Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta

Advances in Pharmacology

Volumn 64, Issue , 2012, Pages 27-81

  Cohen, Ann D ^a   Rabinovici, Gil D ^b   Mathis, Chester A ^a   Jagust, William J ^c   Klunk, William E ^a   Ikonomovic, Milos D ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Amyloid; Neuroimaging; Pittsburgh compound B; Positron emission tomography

Indexed keywords

2 1 6 2 F18 FLUOROETHYL METHYL AMINO 2 NAPHTHYL ETHYLIDENE MALONONITRILE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; FLORBETABEN; FLORBETAPIR F 18; FLUTEMETAMOL F 18; GAMMA SECRETASE; MALONONITRILE; PITTSBURGH COMPOUND B; PRESENILIN 2; TAR DNA BINDING PROTEIN; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; BRAIN HEMORRHAGE; CHROMOSOME 21; COGNITION; DOWN SYNDROME; DRUG EFFICACY; FOLLOW UP; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LEWY BODY; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; OCCIPITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VASCULAR AMYLOIDOSIS;

EID: 84864292209     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394816-8.00002-7     Document Type: Chapter

References (278)

1. Agdeppa E.D., Kepe V., Liu J., Flores-Torres S., Satyamurthy N., Petric A., Cole G.M., Small G.W., Huang S.C., Barrio J.R. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. Journal of Neuroscience 2001, 21:RC189.
2. Aizenstein H.J., Nebes R.D., Saxton J.A., Price J.C., Mathis C.A., Tsopelas N.D., Ziolko S.K., James J.A., Snitz.B.E., Houck P.R., Bi W., Cohen A.D., Lopresti B.J., DeKosky S.T., Halligan E.M., Klunk W.E. Frequent amyloid deposition without significant cognitive impairment among the elderly. Archives of Neurology 2008, 65:1509-1517.
3. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011, 7(3):270-279.
4. Alladi S., Xuereb J., Bak T., Nestor P., Knibb J., Patterson K., et al. Focal cortical presentations of Alzheimer's disease. Brain 2007, 130:2636-2645.
5. Anchisi D., Borroni B., Franceschi M., Kerrouche N., Kalbe E., Beuthien-Beumann B., Cappa S., Lenz O., Ludecke S., Marcone A., Mielke R., Ortelli P., Padovani A., Pelati O., Pupi A., Scarpini E., Weisenbach S., Herholz K., Salmon E., Holthoff V., Sorbi S., Fazio F., Perani D. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Archives of Neurology 2005, 62(11):1728-1733.
6. Apostolova L.G., Dinov I.D., Dutton R.A., Hayashi K.M., Toga A.W., Cummings J.L., Thompson P.M. 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease. Brain 2006, 129(Pt 11):2867-2873.
7. Apostolova L.G., Dutton R.A., Dinov I.D., Hayashi K.M., Toga A.W., Cummings J.L., Thompson P.M. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Archives of Neurology 2006, 63(5):693-699.
8. Apostolova L.G., Mosconi L., Thompson P.M., Green A.E., Hwang K.S., Ramirez A., Mistur R., Tsui W.H., de Leon M.J. Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiology of Aging 2008, 31(7):1077-1088. Epub 2008 Sep 24.
9. Archer H.A., Edison P., Brooks D.J., Barnes J., Frost C., Yeatman T., Fox N.C., Rossor M.N. Amyloid load and cerebral atrophy in Alzheimer's disease: An 11C-PIB positron emission tomography study. Annals of Neurology 2006, 60:145-147.
10. Arnáiz E., Jelic V., Almkvist O., Wahlund L.O., Winblad B., Valind S., Nordberg A. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001, 12(4):851-855.
11. Arnold S.E., Hyman B.T., Flory J., Damasio A.R., Van Hoesen G.W. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cerebral Cortex 1991, 1:103-116.
12. Attems J., Quass M., Jellinger K.A., Lintner F. Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. Journal of the Neurological Sciences 2007, 257:49-55.
13. Bacskai B.J., Frosch M.P., Freeman S.H., Raymond S.B., Augustinack J.C., Johnson K.A., Irizarry M.C., Klunk W.E., Mathis C.A., Dekosky S.T., Greenberg S.M., Hyman B.T., Growdon J.H. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: A case report. Archives of Neurology 2007, 64:431-434.
14. Baker S., Landau S., Jagust W. Effect of white matter binding on florbetapir and PIB image classification 2012, Human Amyloid Imaging, Miami, FL.
15. Ballard C., Ziabreva I., Perry R., Larsen J.P., O'Brien J., McKeith I., Perry E., Aarsland D. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006, 67(11):1931-1934.
16. Barthel H., Gertz H.J., Dresel S., Peters O., Bartenstein P., Buerger K., et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: A multicentre phase 2 diagnostic study. Lancet Neurology, 10 2011, 424-435.
17. Barthel H., Luthardt J., Becker G., Patt M., Hammerstein E., Hartwig K., Eggers B., Sattler B., Schildan A., Hesse S., Meyer P.M., Wolf H., Zimmermann T., Reischl J., Rohde B., Gertz H.J., Reininger C., Sabri O. Individualized quantification of brain β-amyloid burden: Results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. European Journal of Nuclear Medicine and Molecular Imaging 2011, 38(9):1702-1714.
18. Bateman R.J., Aisen P.S., De Strooper B., Fox N.C., Lemere C.A., Ringman J.M., et al. Autosomal-dominant Alzheimer's disease: A review and proposal for the prevention of Alzheimer's disease. Alzheimer's Research & Therapy 2011, 3:1.
19. Becker J.T., Davis S.W., Hayashi K.M., Meltzer C.C., Toga A.W., Lopez O.L., Thompson P.M. Three-dimensional patterns of hippocampal atrophy in mild cognitive impairment. Archives of Neurology 2006, 63(1):97-101. Imaging Methods and Analysis in Geriatrics Research Group.
20. Bennett D.A., Schneider J.A., Arvanitakis Z., Kelly J.F., Aggarwal N.T., Shah R.C., Wilson R.S. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006, 66(12):1837-1844.
21. Bennett J.P., Yamamura H.I. Neurotransmitter, hormone, or drug receptor binding methods. Neurotransmitter receptor binding 1985, 61-89. Raven Press, New York. H.I. Yamamura, S.J. Enna, M.J. Kuhar (Eds.).
22. Berg L., McKeel D.W.J., Miller J.P., Storandt M., Rubin E.H., Morris J.C., Baty J., Coats M., Norton J., Goate A.M., Price J.L., Gearing M., Mirra S.S., Saunders A.M. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Archives of Neurology 1998, 55:326-335.
23. Blennow K. CSF biomarkers for mild cognitive impairment. Journal of Internal Medicine 2004, 256(3):224-234.
24. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurology 2003, 2(10):605-613.
25. Bombois S., Maurage C.A., Gompel M., Deramecourt V., Mackowiak-Cordoliani M.A., Black R.S., Lavielle R., Delacourte A., Pasquier F. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Archives of Neurology 2007, 64:583-587.
26. Boche D., Denham N., Holmes C., Nicoll J.A. Neuropathology after active Abeta42 immunotherapy: Implications for Alzheimer's disease pathogenesis. Acta Neuropathologica 2010 Sep, 120(3):369-384. Epub 2010 Jul 15.
27. Bourgeat P., Chetelat G., Villemagne V.L., Fripp J., Raniga P., Pike K., Acosta O., Szoeke C., Ourselin S., Ames D., Ellis K.A., Martins R.N., Masters C.L., Rowe C.C., Salvado O. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010, (74):121-127.
28. Boxer A.L., Rabinovici G.D., Kepe V., Goldman J., Furst A.J., Huang S.C., Baker S.L., O'Neil J.P., Chui H., Geschwind M.D., Small G.W., Barrio J.R., Jagust W., Miller B.L. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology 2007, 69:283-290.
29. Braak H., Braak E. Alzheimer's disease: Striatal amyloid deposits and neurofibrillary changes. Journal of Neuropathology & Experimental Neurology 1990, 49:215-224.
30. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica (Berlin) 1991, 82:239-259.
31. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging 2003, 24:197-211.
32. Brilliant M.J., Elble R.J., Ghobrial M., Struble R.G. The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer's disease. Neuropathology and Applied Neurobiology 1997, 23:322-325.
33. Buchhave P., Minthon L., Zetterberg H., Wallin A.K., Blennow K., Hansson O. Cerebrospinal fluid levels of β-Amyloid 1-42, but not of Tau, are fully changed already 5-10 years before the onset of Alzheimer dementia. Archives of General Psychiatry 2012, 69(1):98-106.
34. Buckner R.L., Snyder A.Z., Shannon B.J., LaRossa G., Sachs R., Fotenos A.F., Sheline Y.I., Klunk W.E., Mathis C.A., Morris J.C., Mintun M.A. Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. Journal of Neuroscience 2005, 25:7709-7717.
35. Burack M.A., Hartlein J., Flores H.P., Taylor-Reinwald L., Perlmutter J.S., Cairns N.J. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010, 74(1):77-84.
36. Busse A., Hensel A., Guhne U., Angermeyer M.C., Riedel-Heller S.G. Mild cognitive impairment: Long-term course of four clinical subtypes. Neurology 2006, 67:2176-2185.
37. Cairns N.J., Ikonomovic M.D., Benzinger T., Storandt M., Fagan A.M., Shah A.R., Reinwald L.T., Carter D., Felton A., Holtzman D.M., Mintun M.A., Klunk W.E., Morris J.C. Absence of Pittsburgh compound B detec tion of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: A case report. Archives of Neurology 2009, 66(12):1557-1562.
38. Camus V., Payoux P., Barré L., Desgranges B., Voisin T., Tauber C., La Joie R., Tafani M., Hommet C., Chételat G., Mondon K., de La Sayette V., Cottier J.P., Beaufils E., Ribeiro M.J., Gissot V., Vierron E., Vercouillie J., Vellas B., Eustache F., Guilloteau D. Using PET with (18)F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. European Journal of Nuclear Medicine and Molecular Imaging 2012, [Epub ahead of print].
39. Chetelat G., Villemagne V.L., Villain N., Jones G., Ellis K.A., Ames D., Masters C.L., Rowe C.C., Martins R.N. Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology 2012, 78(7):477-484. AIBL Research Group.
40. Chételat G., Desgranges B., de la Sayette V., Viader F., Eustache F., Baron J.C. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 2003, 60(8):1374-1377.
41. Chételat G., Desgranges B., de la Sayette V., Viader F., Berkouk K., Landeau B., Lalevée C., Le Doze F., Dupuy B., Hannequin D., Baron J.C., Eustache F. Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain 2003, 126(Pt 9):1955-1967.
42. Chételat G., Fouquet M., Kalpouzos G., Denghien I., De la Sayette V., Viader F., Mézenge F., Landeau B., Baron J.C., Eustache F., Desgranges B. Three-dimensional surface mapping of hippocampal atrophy progression from MCI to AD and over normal aging as assessed using voxel-based morphometry. Neuropsychologia 2008, 46(6):1721-1731.
43. Chételat G., Villemagne V.L., Bourgeat P., Pike K.E., Jones G., Ames D., Ellis K.A., Szoeke C., Martins R.N., O'Keefe G.J., Salvado O., Masters C.L., Rowe C.C. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Annals of Neurology 2010, 67(3):317-324. Australian Imaging Biomarkers and Lifestyle Research Group.
44. Choi S.R., Golding G., Zhuang Z., Zhang W., Lim N., Hefti F., Benedum T.E., Kilbourn M.R., Skovronsky D., Kung H.F. Preclinical properties of 18F-AV-45: A PET agent for Abeta plaques in the brain. Journal of Nuclear Medicine 2009, 50(11):1887-1894.
45. Claassen D.O., Lowe V.J., Peller P.J., Petersen R.C., Josephs K.A. Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy. Parkinsonism & Related Disorders 2011, 17(3):160-165.
46. Clark C.M., Schneider J.A., Bedell B.J., Beach T.G., Bilker W.B., Mintun M.A., et al. Use of florbetapir-PET for imaging beta-amyloid pathology. The Journal of the American Medical Association 2011, 305:275-283.
47. Cohen A.D., Price J.C., Weissfeld L.A., James J., Rosario B.L., Bi W., Nebes R.D., Saxton J.A., Snitz B.E., Aizenstein H.A., Wolk D.A., DeKosky S.T., Mathis C.A., Klunk W.E. Basal cerebral metabolism may modulate the cognitive effects of Aβ in mild cognitive impairment: An example of brain reserve. Journal of Neuroscience 2009, 29:14770-14778.
48. Conway K.AJr, Harper J.D., Lansbury P.T. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000, 39:2552-2563.
49. DeKosky S.T., Mathis C.M., Price J.C., Ikonomovic M.D., Hamilton R.L., Abrahamson E.E., Paljug W.R., Debnath M.L., Hope C.E., Isanski B.A., Tsopelas N.D., Lopresti B.J., Ziolko S., Bi W., Klunk W.E. Correlation of regional in vivo Pittsburgh compound-B (PIB) retention with in vitro PIB, Aβ levels, and amyloid plaque density: Validation of PIB-PET in postmortem human brain. Alzheimer's & Dementia 2007, 3:S105.
50. DeKosky S.T., Ikonomovic M.D., Styren S.D., Beckett L., Wisniewski S., Cochran E.J., Kordower J.H., Mufson E.J., Bennett D.A. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Annals of Neurology 2002, 51(2):145-155.
51. DeKosky S.T., Scheff S.W., Styren S.D. Structural correlates of cognition in dementia: Quantification and assessment of synapse change. Neurodegeneration 1996, 5(4):417-421.
52. Del Sole A., Clerici F., Chiti A., Lecchi M., Mariani C., Maggiore L., Mosconi L., Lucignani G. Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: An FDG PET study. European Journal of Nuclear Medicine and Molecular Imaging 2008, 35(7):1357-1366.
53. de Souza L.C., Corlier F., Habert M.O., Uspenskaya O., Maroy R., Lamari F., et al. Similar amyloid-beta burden in posterior cortical atrophy and Alzheimer's disease. Brain 2011, 134:2036-2043.
54. de Toledo-Morrell L., Stoub T.R., Bulgakova M., Wilson R.S., Bennett D.A., Leurgans S., Wuu J., Turner D.A. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiology of Aging 2004, 25(9):1197-1203.
55. Devanand D.P., Pradhaban G., Liu X., Khandji A., De Santi S., Segal S., Rusinek H., Pelton G.H., Honig L.S., Mayeux R., Stern Y., Tabert M.H., de Leon M.J. Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction of Alzheimer disease. Neurology 2007, 68(11):828-836.
56. Dickson D.W. Dementia with Lewy bodies: Neuropathology. Journal of Geriatric Psychiatry and Neurology 2002, 15:210-216.
57. Dierksen G.A., Skehan M.E., Khan M.A., Jeng J., Nandigam R.N., Becker J.A., Kumar A., Neal K.L., Betensky R.A., Frosch M.P., Rosand J., Johnson K.A., Viswanathan A., Salat D.H., Greenberg S.M. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy. Annals of Neurology 2010, 68(4):545-548.
58. Driscoll I., Zhou Y., An Y., Sojkova J., Davatzikos C., Kraut M.A., Ye W., Ferrucci L., Mathis C.A., Klunk W.E., Wong D.F., Resnick S.M. Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals. Neurobiology of Aging 2010, 32(12):2123-2130.
59. Drzezga A., Grimmer T., Henriksen G., Stangier I., Perneczky R., Diehl-Schmid J., Mathis C.A., Klunk W.E., Price J., Dekosky S., Wester H.J., Schwaiger M., Kurz A. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 2008, 39:619-633.
60. Drzezga A., Grimmer T., Riemenschneider M., Lautenschlager N., Siebner H., Alexopoulus P., Minoshima S., Schwaiger M., Kurz A. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. Journal of Nuclear Medicine 2005, 46(10):1625-1632.
61. Edison P., Archer H.A., Hinz R., Hammers A., Pavese N., Tai Y.F., Hotton G., Cutler D., Fox N., Kennedy A., Rossor M., Brooks D.J. Amyloid, hypometabolism, and cognition in Alzheimer disease. An [11C]PIB and [18F]FDG PET study. Neurology 2006, 68:501-508.
62. Edison P., Rowe C.C., Rinne J.O., Ng S., Ahmed I., Kemppainen N., Villemagne V.L., O'Keefe G., Nagren K., Chaudhury K.R., Masters C.L., Brooks D.J. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. Journal of Neurology, Neurosurgery, and Psychiatry 2008, 79:1331-1338.
63. Edison P., Archer H.A., Gerhard A., Hinz R., Pavese N., Turkheimer F.E., Hammers A., Tai Y.F., Fox N., Kennedy A., Rossor M., Brooks D.J. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiology of Disease 2008, 32(3):412-419.
64. Engler H., Santillo A.F., Wang S.X., Lindau M., Savitcheva I., Nordberg A., Lannfelt L., Langstrom B., Kilander L. In vivo amyloid imaging with PET in frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging 2007, 35:100-106.
65. Engler H., Forsberg A., Almkvist O., Blomquist G., Larsson E., Savitcheva I., Wall A., Ringheim A., Langstrom B., Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006, 129:2856-2866.
66. Engler H., Nordberg A., Blomqvist G., Bergström M., Estrada S., Barletta J., Sandell J., Antoni G., Långström B., Klunk W.E., Debnath M.L., Holt D.P., Wang Y., Huang G.-F., Mathis C.A. First human study with a benzothiazole amyloid-imaging agent in Alzheimer's disease and control subjects. Neurobiology of Aging 2002, 23(1S):S429.
67. Fagan A.M., Mintun M.A., Shah A.R., Aldea P., Roe C.M., Mach R.H., Marcus D., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Molecular Medicine, 1 2009, 371-380.
68. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Archives of Neurology 2007, 64:343-349.
69. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., Larossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., Dekosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans. Annals of Neurology 2006, 59:512-519.
70. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. The Journal of the American Medical Association 1997, 278(16):1349-1356.
71. Fleisher A.S., Chen K., Liu X., Roontiva A., Thiyyagura P., Ayutyanont N., Joshi A.D., Clark C.M., Mintun M.A., Pontecorvo M.J., Doraiswamy P.M., Johnson K.A., Skovronsky D.M., Reiman E.M. Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Archives of Neurology 2011, 68(11):1404-1411.
72. Fodero-Tavoletti M.T., Okamura N., Furumoto S., Mulligan R.S., Connor A.R., McLean C.A., Cao D., Rigopoulos A., Cartwright G.A., O'Keefe G., Gong S., Adlard P.A., Barnham K.J., Rowe C.C., Masters C.L., Kudo Y., Cappai R., Yanai K., Villemagne V.L. 18F-THK523: A novel in vivo tau imaging ligand for Alzheimer's disease. Brain 2011, 134(Pt 4):1089-1100.
73. Fodero-Tavoletti M.T., Rowe C.C., McLean C.A., Leone L., Li Q.X., Masters C.L., et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. Journal of Nuclear Medicine 2009, 50:198-204.
74. Fodero-Tavoletti M.T., Smith D.P., McLean C.A., Adlard P.A., Barnham K.J., Foster L.E., Leone L., Perez K., Cortés M., Culvenor J.G., Li Q.X., Laughton K.M., Rowe C.C., Masters C.L., Cappai R., Villemagne V.L. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. Journal of Neuroscience 2007, 27(39):10365-10371.
75. Fodero-Tavoletti M., Cappai R., Krause S., Lippoldt A., Foster L., Leone L., Smith D., McLean C., Rowe C.C., Dyrks T., Masters C.L., Villemagne V.L. In vitro characterization of PIB binding to α-synuclein. Alzheimer's & Dementia 2006, 2:S333-S334.
76. Formaglio M., Costes N., Seguin J., Tholance Y., Le Bars D., Roullet-Solignac I., et al. In vivo demonstration of amyloid burden in posterior cortical atrophy: A case series with PET and CSF findings. Journal of Neurology 2011, 258:1841-1851.
77. Forman M.S., Farmer J., Johnson J.K., Clark C.M., Arnold S.E., Coslett H.B., et al. Frontotemporal dementia: Clinicopathological correlations. Annals of Neurology 2006, 59:952-962.
78. Forsberg A., Almkvist O., Engler H., Wall A., Langstrom B., Nordberg A. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Current Alzheimer Research 2010, 7:56-66.
79. Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., Ringheim A., Langstrom B., Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiology of Aging. 2007 2007, 29(10):1456-1465.
80. Foster E.R., Campbell M.C., Burack M.A., Hartlein J., Flores H.P., Cairns N.J., Hershey T., Perlmutter J.S. Amyloid imaging of Lewy body-associated disorders. Movement Disorders 2010, 25(15):2516-2523.
81. Foster N.L., Heidebrink J.L., Clark C.M., Jagust W.J., Arnold S.E., Barbas N.R., et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007, 130:2616-2635.
82. Fotenos A.F., Mintun M.A., Snyder A.Z., Morris J.C., Buckner R.L. Brain volume decline in aging: Evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Archives of Neurology 2008, 65(1):113-120.
83. Friedland R.P., Budinger T.F., Ganz E., Yano Y., Mathis C.A., Koss B., Ober B.A., Huesman R.H., Derenzo S.E. Regional cerebral metabolic alterations in dementia of the Alzheimer type: Positron emission tomography with [18F]fluorodeoxyglucose. Journal of Computer Assisted Tomography 1983, 7(4):590-598.
84. Frisoni G.B., Lorenzi M., Caroli A., Kemppainen N., Någren K., Rinne J.O. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 2009, 72(17):1504-1511.
85. Furney S.J., Kronenberg D., Simmons A., Güntert A., Dobson R.J., Proitsi P., Wahlund L.O., Kloszewska I., Mecocci P., Soininen H., Tsolaki M., Vellas B., Spenger C., Lovestone S. Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease-cytokines and MRI measures together predict disease progression. J Alzheimers Dis 2011, 3(Suppl. 26):395-405.
86. Furst A.J., Rabinovici G.D., Rostomian A.H., Steed T., Alkalay A., Racine C., Miller B.L., Jagust W.J. Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiology of Aging 2010, 33(2):215-225.
87. Garibotto V., Borroni B., Kalbe E., Herholz K., Salmon E., Holtoff V., Sorbi S., Cappa S.F., Padovani A., Fazio F., Perani D. Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence. Neurology 2008, 71(17):1342-1349.
88. Gauthier S., Reisberg B., Zaudig M., Petersen R.C., Ritchie K., Broich K., Belleville S., Brodaty H., Bennett D., Chertkow H., Cummings J.L., de Leon M., Feldman H., Ganguli M., Hampel H., Scheltens P., Tierney M.C., Whitehouse P., Winblad B. Mild cognitive impairment. Lancet 2006, 367:1262-1270.
89. Gomez-Isla T., West H.L., Rebeck G.W., Harr S.D., Growdon J.H., Locascio J.J., Perls T.T., Lipsitz L.A., Hyman B.T. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Annals of Neurology 1996, 39(1):62-70.
90. Gomperts S.N., Rentz D.M., Moran E., Becker J.A., Locascio J.J., Klunk W.E., Mathis C.A., Elmaleh D.R., Shoup T., Fischman A.J., Hyman B.T., Growdon J.H., Johnson K.A. Imaging amyloid deposition in Lewy body diseases. Neurology 2008, 71(12):903-910.
91. Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., et al. Classification of primary progressive aphasia and its variants. Neurology 2011, 76:1006-1014.
92. Gorno-Tempini M.L., Dronkers N.F., Rankin K.P., Ogar J.M., Phengrasamy L., Rosen H.J., et al. Cognition and anatomy in three variants of primary progressive aphasia. Annals of Neurology 2004, 55:335-346.
93. Greenberg S.M., Grabowski T., Gurol M.E., Skehan M.E., Nandigam R.N., Becker J.A., Garcia-Alloza M., Prada C., Frosch M.P., Rosand J., Viswanathan A., Smith E.E., Johnson K.A. Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Annals of Neurology 2008, 64(5):587-591.
94. Grimmer T., Alexopoulos P., Tsolakidou A., Guo L.H., Henriksen G., Yousefi B.H., Förstl H., Sorg C., Kurz A., Drzezga A., Perneczky R. Cerebrospinal fluid BACE1 activity and brain amyloid load in Alzheimer's disease. Scientific World Journal 2012, 2012:712048.
95. Grimmer T., Tholen S., Yousefi B.H., Alexopoulos P., Förschler A., Förstl H., Henriksen G., Klunk W.E., Mathis C.A., Perneczky R., Sorg C., Kurz A., Drzezga A. Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease. Biological Psychiatry 2010, 68(10):879-884.
96. Grimmer T., Riemenschneider M., Forstl H., Henriksen G., Klunk W.E., Mathis C.A., Shiga T., Wester H.J., Kurz A., Drzezga A. Beta amyloid in Alzheimer's disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biological Psychiatry 2009, (65):927-934.
97. Grundman M., Sencakova D., Jack C.R., Petersen R.C., Kim H.T., Schultz A., Weiner M.F., DeCarli C., DeKosky S.T., van Dyck C., Thomas R.G., Thal L.J., Alzheimer's Disease Cooperative Study Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. Journal of Molecular Neuroscience 2002, 19(1-2):23-27.
98. Handen B, Cohen AD, Channamalappa U, Bulova P, Cannon SA, Cohen WI, Mathis CA, Price JC, & Klunk WE. (In press). Imaging brain amyloid in non-demented young adults with Down syndrome using Pittsburgh Compound-B. Alzheimer's & Dementia.
99. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends in Pharmacological Sciences 1991, 12:383-388.
100. Hardy J., Duff K., Hardy K.G., Perez-Tur J., Hutton M. Genetic dissection of Alzheimer's disease and related dementias: Amyloid and its relationship to tau. Nature Neuroscience 1998, 1:355-358.
101. Hardy J.A., Higgins G.A. Alzheimer's disease: The amyloid cascade hypothesis. Science 1992, 256:184-185.
102. Haroutunian V., Perl D., Purohit D., Marin D., Khan K., Lantz M., Davis K. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer's disease. Archives of Neurology 1998, 55:1185-1191.
103. Hedden T., Van Dijk K.R., Becker J.A., Mehta A., Sperling R.A., Johnson K.A., Buckner R.L. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. Journal of Neuroscience 2009, 29(40):12686-12694.
104. Herholz K., Carter S.F., Jones M. Positron emission tomography imaging in dementia. The British Journal of Radiology 2007, 80:S160-S167.
105. Ikonomovic M.D., Abrahamson E.E., Price J.C., Hamilton R.L., Mathis C.A., Paljug W.R., Debnath M.L., Cohen A.D., Mizukami K., Dekosky S.T., Lopez O.L., Klunk W.E. Early AD pathology in a [C-11]PiB-negative case: A PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathologica 2012, 123(3):433-447.
106. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., Lopresti B.J., Ziolko S., Bi W., Paljug W.R., Debnath M.L., Hope C.E., Isanski B.A., Hamilton R.L., DeKosky S.T. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
107. Ikonomovic M.D., Abrahamson E.E., Isanski B.A., Wuu J., Mufson E.J., DeKosky S.T. Superior frontal cortex cholinergic axon density in mild cognitive impairment and early Alzheimer disease. Archives of Neurology 2007, 64(9):1312-1317.
108. Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., Thies B., Phelps C.H. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011, 7(3):257-262.
109. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., Weiner M., Petersen R.C., the Alzheimer's Disease Neuroimaging I Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132(Pt 5):1355-1365.
110. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., Petersen R.C. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
111. Jack C.R., Petersen R.C., Xu Y., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Tangalos E.G., Kokmen E. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000, 55(4):484-489.
112. Jack C.R., Petersen R.C., Xu Y.C., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Waring S.C., Tangalos E.G., Kokmen E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999, 52(7):1397-1403.
113. Jagust W., Reed B., Mungas D., Ellis W., Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology 2007, 69:871-877.
114. Jellinger K.A. Alzheimer disease and cerebrovascular pathology: An update. Journal of Neural Transmission 2002, 109:813-836.
115. Jellinger K.A. Prevalence of Alzheimer lesions in Parkinson's disease. Movement Disorders 2003, 18:1207-1208.
116. Johansson A., Savitcheva I., Forsberg A., Engler H., Langstrom B., Nordberg A., Askmark H. [(11)C]-PIB imaging in patients with Parkinson's disease: Preliminary results. Parkinsonism & Related Disorders 2007, 14(4):345-347.
117. Johnson A.E., Jeppsson F., Sandell J., Wensbo D., Neelissen J.A., Juréus A., Ström P., Norman H., Farde L., Svensson S.P. AZD2184: A radioligand for sensitive detection of beta-amyloid deposits. Journal of Neurochemistry 2009, 108(5):1177-1186.
118. Johnson K.A., Gregas M., Becker J.A., Kinnecom C., Salat D.H., Moran E.K., Smith E.E., Rosand J., Rentz D.M., Klunk W.E., Mathis C.A., Price J.C., Dekosky S.T., Fischman A.J., Greenberg S.M. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Annals of Neurology 2007, 62(3):229-234.
119. Johnson J., Head E., Kim R., Starr A., Cotman C. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Archives of Neurology 1999, 56:1233-1239.
120. Johnson J.K., Diehl J., Mendez M.F., Neuhaus J., Shapira J.S., Forman M., et al. Frontotemporal lobar degeneration: Demographic characteristics of 353 patients. Arch Neurol 2005, 62:925-930.
121. Juréus A., Swahn B.M., Sandell J., Jeppsson F., Johnson A.E., Johnström P., Neelissen J.A., Sunnemark D., Farde L., Svensson S.P. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. Journal of Neurochemistry 2010.
122. Kadir A., Marutle A., Gonzalez D., Schöll M., Almkvist O., Mousavi M., Mustafiz T., Darreh-Shori T., Nennesmo I., Nordberg A. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain 2011, 134(Pt 1):301-317.
123. Kalaitzakis M.E., Walls A.J., Pearce R.K., Gentleman S.M. Striatal Aβ peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes. Neurobiology of Disease 2011, 41(2):377-384.
124. Kantarci K., Lowe V., Przybelski S.A., Weigand S.D., Senjem M.L., Ivnik R.J., Preboske G.M., Roberts R., Geda Y.E., Boeve B.F., Knopman D.S., Petersen R.C., Jack C.R. APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology 2012, 78(4):232-240.
125. Kantarci K., Yang C., Schneider J.A., Senjem M.L., Reyes D.A., Lowe V.J., Barnes L.L., Aggarwal N.T., Bennett D.A., Smith G.E., Petersen R.C., Jack C.R., Boeve B.F. Ante mortem amyloid imaging and B-amyloid pathology in a case with dementia with Lewy bodies. Neurobiology of Aging 2010, 2010 Oct 18 [Epub ahead of print].
126. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. Journal of Neuroscience 2001, 21(2):372-381.
127. Kemppainen N.M., Aalto S., Wilson I.A., Nagren K., Helin S., Bruck A., Oikonen V., Kailajarvi M., Scheinin M., Viitanen M., Parkkola R., Rinne J.O. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006, 67:1575-1580.
128. Kemppainen N.M., Aalto S., Wilson I.A., Nagren K., Helin S., Bruck A., Oikonen V., Kailajarvi M., Scheinin M., Viitanen M., Parkkola R., Rinne J.O. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007, 68:1603-1606.
129. Khachaturian Z.S. Diagnosis of Alzheimer's disease. Archives of Neurology 1985, 42:1097-1105.
130. Klunk W.E., Wang Y., Huang G.F., Debnath M.L., Holt D.P., Shao L., Hamilton R.L., Ikonomovic M.D., DeKosky S.T., Mathis C.A. The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. Journal of Neuroscience 2003, 23:2086-2092.
131. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.F., Shao L., DeKosky S.T., Price J.C., Mathis C.A. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. Journal of Neuroscience 2005, 25:10598-10606.
132. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G.F., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology 2004, 55:306-319.
133. Klunk W.E., Price J.C., Mathis C.A., Tsopelas N.D., Lopresti B.J., Ziolko S.K., Bi W., Hoge J.A., Cohen A.D., Ikonomovic M.D., Saxton J.A., Snitz B.E., Pollen D.A., Moonis M., Lippa C.F., Swearer J.M., Johnson K.A., Rentz D.M., Fischman A.J., Aizenstein H.J., DeKosky S.T. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. Journal of Neuroscience 2007, 27:6174-6184.
134. Koeppe R.A. Basic principles and controversies in PET amyloid imaging 2012, Human Amyloid Imaging, Miami, FL.
135. Koeppe R.A., Gilman S., Junck L., Wernette K., Frey K.A. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimer's & Dementia 2008, 4(1 Suppl. 1):S67-S76.
136. Koivunen J., Scheinin N., Virta J.R., Aalto S., Vahlberg T., Någren K., Helin S., Parkkola R., Viitanen M., Rinne J.O. Amyloid PET imaging in patients with mild cognitive impairment: A 2-year follow-up study. Neurology 2011, 76(12):1085-1090.
137. Koivunen J., Pirttilä T., Kemppainen N., Aalto S., Herukka S.K., Jauhianen A.M., Hänninen T., Hallikainen M., Någren K., Rinne J.O., Soininen H. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dementia and Geriatric Cognitive Disorders 2008, 26(4):378-383.
138. Kok E., Haikonen S., Luoto T., Huhtala H., Goebeler S., Haapasalo H., Karhunen P.J. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Annals of Neurology 2009, 65(6):650-657.
139. Laforce R., Rabinovici G.D. Amyloid imaging in the differential diagnosis of dementia: Review and potential clinical applications. Alzheimer's Research & Therapy 2011, 3:31.
140. Landt J., D'Abrera J.C., Holland A.J., Aigbirhio F.I., Fryer T.D., Canales R., Hong Y.T., Menon D.K., Baron J.C., Zaman S.H. Using positron emission tomography and Carbon 11-labeled Pittsburgh compound B to image brain fibrillar β-amyloid in adults with down syndrome: Safety, acceptability, and feasibility. Archives of Neurology 2011, 68(7):890-896.
141. Lee S.E., Rabinovici G.D., Mayo M.C., Wilson S.M., Seeley W.W., DeArmond S.J., et al. Clinicopathological correlations in corticobasal degeneration. Annals of Neurology 2011, 70:327-340.
142. Leinonen V., Alafuzoff I., Aalto S., Suotunen T., Savolainen S., Nagren K., Tapiola T., Pirttila T., Rinne J., Jaaskelainen J.E., Soininen H., Rinne J.O. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B. Archives of Neurology 2008, 65(10):1304-1309.
143. Levine H. Soluble multimeric Alzheimer beta(1-40) pre-amyloid complexes in dilute solution. Neurobiology of Aging 1995, 16(5):755-764.
144. Leyton C.E., Villemagne V.L., Savage S., Pike K.E., Ballard K.J., Piguet O., et al. Subtypes of progressive aphasia: Application of the international consensus criteria and validation using {beta}-amyloid imaging. Brain 2011, 134:3030-3043.
145. Li Y., Rinne J., Mosconi L., Pirraglia E., Rusinek H., DeSanti S., Kemppainen N., Någren K., Kim B.-C., Tsui W., de Leon M. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging 2008, 35:2169-2181.
146. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A., Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. Journal of Neuroscience 2000, 20(15):5709-5714.
147. Lin K.J., Hsu W.C., Hsiao I.T., Wey S.P., Jin L.W., Skovronsky D., Wai Y.Y., Chang H.P., Lo C.W., Yao C.H., Yen T.C., Kung M.P. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent - a pilot study. Nuclear Medicine and Biology 2010, 37(4):497-508.
148. Lister-James J., Pontecorvo M.J., Clark C., Joshi A.D., Mintun M.A., Zhang W., Lim N., Zhuang Z., Golding G., Choi S.R., Benedum T.E., Kennedy P., Hefti F., Carpenter A.P., Kung H.F., Skovronsky D.M. Florbetapir f-18: A histopathologically validated Beta-amyloid positron emission tomography imaging agent. Seminars in Nuclear Medicine 2011, 41(4):300-304.
149. Lockhart A., Lamb J.R., Osredkar T., Sue L.I., Joyce J.N., Ye L., Libri V., Leppert D., Beach T.G. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007, 130(Pt 10):2607-2615.
150. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. Journal of Cerebral Blood Flow and Metabolism 1996, 16(5):834-840.
151. Lopresti B.J., Klunk W.E., Mathis C.A., Hoge J.A., Ziolko S.K., Lu X., Meltzer C.C., Schimmel K., Tsopelas N.D., Dekosky S.T., Price J.C. Simplified quantification of Pittsburgh compound B amyloid imaging PET Studies: A comparative analysis. Journal of Nuclear Medicine 2005, 46:1959-1972.
152. Lorenzi M., Donohue M., Paternicò M., Scarpazza C., Ostrowitzki S., Blin O., Irving E., Frisoni G.B. Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment. Neurobiology of Aging 2010, 31(8):1443-1451. The Alzheimer's Disease Neuroimaging Initiative.
153. Lowe V.J., Kemp B.J., Jack C.R., Senjem M., Weigand S., Shiung M., Smith G., Knopman D., Boeve B., Mullan B., Petersen R.C. Comparison of 18F-FDG and PiB PET in Cognitive Impairment. Journal of Nuclear Medicine 2009, 50(6):878-886.
154. Ly J.V., Donnan G.A., Villemagne V.L., Zavala J.A., Ma H., O'Keefe G., Gong S.J., Gunawan R.M., Saunder T., Ackerman U., Tochon-Danguy H., Churilov L., Phan T.G., Rowe C.C. 11C-PIB binding is increased in patients with cerebral amyloid angiopathy-related hemorrhage. Neurology 2010, 74(6):487-493.
155. Mackenzie I.R., Neumann M., Bigio E.H., Cairns N.J., Alafuzoff I., Kril J., et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica 2010, 119:1-4.
156. Maetzler W., Liepelt I., Reimold M., Reischl G., Solbach C., Becker C., Schulte C., Leyhe T., Keller S., Melms A., Gasser T., Berg D. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiology of Disease 2009, 34:107-112.
157. Maetzler W., Reimold M., Liepelt I., Solbach C., Leyhe T., Schweitzer K., Eschweiler G.W., Mittelbronn M., Gaenslen A., Uebele M., Reischl G., Gasser T., Machulla H.J., Bares R., Berg D. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008, 39:1027-1033.
158. Mahley R.W., Weisgraber K.H., Huang Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(15):5644-5651.
159. Maia L.F., Mackenzie I.R., Feldman H.H. Clinical phenotypes of cerebral amyloid angiopathy. Journal of the Neurological Sciences 2007, 257:23-30.
160. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., Schenk D. Ab vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005, 64:129-131.
161. Mastaglia F.L., Johnsen R.D., Byrnes M.L., Kakulas B.A. Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease. Movement Disorders 2003, 18:81-86.
162. Mathis C.A., Lopresti B., Mason N., Price J., Flatt N., Bi W., Ziolko S., DeKosky S., Klunk W. Comparison of the amyloid imaging agents [F-18]3'-F-PIB and [C-11]PIB in Alzheimer's disease and control subjects. Indian Journal of Nuclear Medicine 2007, 48:56.
163. Mathis C.A., Wang Y., Holt D.P., Huang G.F., Debnath M.L., Klunk W.E. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. Journal of Medicinal Chemistry 2003, 46:2740-2754.
164. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S.K., van der Flier W.M., Blankenstein M.A., Ewers M., Rich K., Kaiser E., Verbeek M., Tsolaki M., Mulugeta E., Rosén E., Aarsland D., Visser P.J., Schröder J., Marcusson J., de Leon M., Hampel H., Scheltens P., Pirttilä T., Wallin A., Jönhagen M.E., Minthon L., Winblad B., Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. The Journal of the American Medical Association 2009, 302(4):385-393.
165. McGeer E.G., McGeer P.L. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: A field in its infancy. J Alzheimers Dis 2010, 19(1):355-361.
166. McKeith I.G. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. Journal of Alzheimer's Disease 2006, 9:417-423.
167. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., Salmon D.P., Lowe J., Mirra S.S., Byrne E.J., Lennox G., Quinn N.P., Edwardson J.A., Ince P.G., Bergeron C., Burns A., Miller B.L., Lovestone S., Collerton D., Jansen E.N., Ballard C., de Vos R.A., Wilcock G.K., Jellinger K.A., Perry R.H. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996, 47(5):1113-1124.
168. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011, 7(3):263-269.
169. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
170. Mesulam M., Wicklund A., Johnson N., Rogalski E., Leger G.C., Rademaker A., et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Annals of Neurology 2008, 63:709-719.
171. Mevel K., Desgranges B., Baron J.C., Landeau B., De la Sayette V., Viader F., Eustache F., Chételat G. Detecting hippocampal hypometabolism in mild cognitive impairment using automatic voxel-based approaches. Neuroimage 2007, 37(1):18-25. Epub 2007 May 8.
172. 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
173. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
174. Moretti D.V., Miniussi C., Frisoni G.B., Geroldi C., Zanetti O., Binetti G., Rossini P.M. Hippocampal atrophy and EEG markers in subjects with mild cognitive impairment. Clinical Neurophysiology 2007, 118(12):2716-2729.
175. Mormino E.C., Brandel M.G., Madison C.M., Rabinovici G.D., Marks S., Baker S.L., Jagust W.J. Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage 2011, 59(3):2362-2373.
176. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., Koeppe R.A., Mathis C.A., Weiner M.W., Jagust W.J. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
177. Morra J.H., Tu Z., Apostolova L.G., Green A.E., Avedissian C., Madsen S.K., Parikshak N., Hua X., Toga A.W., Jack C.R., Schuff N., Weiner M.W., Thompson P.M., Alzheimer's Disease Neuroimaging Initiative Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Human Brain Mapping 2009, 30(9):2766-2788.
178. Morris J.C., Roe C.M., Xiong C., Fagan A.M., Goate A.M., Holtzman D.M., et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Annals of Neurology 2010, 67:122-131.
179. Morris J.C., Price A.L. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. Journal of Molecular Neuroscience 2001, 17:101-118.
180. Morris J.C., Storandt M., McKeel D.W., Rubin E.H., Price J.L., Grant E.A., Berg L. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology 1996, 46:707-719.
181. Mosconi L., Perani D., Sorbi S., Herholz K., Nacmias B., Holthoff V., Salmon E., Baron J.C., De Cristofaro M.T., Padovani A., Borroni B., Franceschi M., Bracco L., Pupi A. MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET. Neurology 2004, 63(12):2332-2340.
182. Mosconi L., De Santi S., Li Y., Li J., Zhan J., Tsui W.H., Boppana M., Pupi A., de Leon M.J. Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. European Journal of Nuclear Medicine and Molecular Imaging 2006, 33(2):210-221.
183. Mosconi L., De Santi S., Li J., Tsui W.H., Li Y., Boppana M., Laska E., Rusinek H., de Leon M.J. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiology of Aging 2008, 29(5):676-692.
184. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., Chang L., Miller B., Clark C., Green R., et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Annals of Neurology 1995, 38:643-648.
185. Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C.R., Jagust W., Trojanowski J.Q., Toga A.W., Beckett L. Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer's & Dementia 2005, 1:55-66.
186. Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C., Jagust W., Trojanowski J.Q., Toga A.W., Beckett L. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clinics of North America 2005, 15:869-877.
187. Nelissen N., Van Laere K., Thurfjell L., Owenius R., Vandenbulcke M., Koole M., Bormans G., Brooks D.J., Vandenberghe R. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. Journal of Nuclear Medicine 2009, 50(8):1251-1259.
188. Nelissen N., Vandenbulcke M., Fannes K., Verbruggen A., Peeters R., Dupont P., Van Laere K., Bormans G., Vandenberghe R. Abeta amyloid deposition in the language system and how the brain responds. Brain 2007, 130:2055-2069.
189. Newell K.L., Hyman B.T., Growdon J.H., Hedley-Whyte E.T. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. Journal of Neuropathology and Experimental Neurology 1999, 58:1147-1155.
190. Ng H., Cheng Y., Poon W. Alzheimer-type of pathological changes in Chinese. Journal of the Neurological Sciences 1997, 97(1):97-103.
191. Ng S.Y., Villemagne V.L., Masters C.L., Rowe C.C. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh compound B. Archives of Neurology 2007, 64:1140-1144.
192. Ng S., Villemagne V.L., Berlangieri S., Lee S.T., Cherk M., Gong S.J., Ackermann U., Saunder T., Tochon-Danguy H., Jones G., Smith C., O'Keefe G., Masters C.L., Rowe C.C. Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. Journal of Nuclear Medicine 2007, 48:547-552.
193. NIA/Reagan_Workgroup Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. Neurobiology of Aging 1997, 18:S1-S2.
194. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-b peptide: A case report. Nature Medicine 2003, 9:448-452.
195. Nilsberth C., Westlind-Danielsson A., Eckman C.B., Condron M.M., Axelman K., Forsell C., Stenh C., Luthman J., Teplow D.B., Younkin S.G., Näslund J., Lannfelt L. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nature Neuroscience 2001, 4(9):887-893.
196. Nitsch R.M., Rebeck G.W., Deng M., Richardson U.I., Tennis M., Schenk D.B., Vigo-Pelfrey C., Lieberburg I., Wurtman R.J., Hyman B.T., et al. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: Inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Annals of Neurology 1995, 37:512-518.
197. Nordberg A., Schöll M., Wall A., Thordadottir S., Ferreira D., Bogdanovic N., Långström B., Almkvist A., Graff C. Arctic APP mutation carriers show low PiB PET retention in the presence of pathological CSF biomarkers and reduced FDG uptake. Neurology 2012, (in press).
198. Ohm T.G., Kirca M., Bohl J., Scharnagl H., Gross W., Marz W. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 1995, 66:583-587.
199. Okello A., Edison P., Archer H.A., Turkheimer F.E., Kennedy J., Bullock R., Walker Z., Kennedy A., Fox N., Rossor M., Brooks D.J. Microglial activation and amyloid deposition in mild cognitive impairment: A PET study. Neurology 2009, 72(1):56-62.
200. Okello A., Koivunen J., Edison P., Archer H.A., Turkheimer F.E., Nagren K., Bullock R., Walker Z., Kennedy A., Fox N.C., Rossor M.N., Rinne J.O., Brooks D.J. Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology 2009, 73:754-760.
201. Ostrowitzki S., Deptula D., Thurfjell L., Barkhof F., Bohrmann B., Brooks D.J., et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with Gantenerumab. Archives of Neurology 2012, 69(2):198-207.
202. Patton R.L., Kalback W.M., Esh C.L., Kokjohn T.A., Van Vickle G.D., Luehrs D.C., Kuo Y.M., Lopez J., Brune D., Ferrer I., Masliah E., Newel A.J., Beach T.G., Castano E.M., Roher A.E. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: A biochemical analysis. The American Journal of Pathology 2006, 169:1048-1063.
203. Perneczky R., Hartmann J., Grimmer T., Drzezga A., Kurz A. Cerebral metabolic correlates of the clinical dementia rating scale in mild cognitive impairment. Journal of Geriatric Psychiatry and Neurology 2007, 20(2):84-88.
204. Pike K.E, G.S, Villemagne V.L., Ng S., Moss S.A., Maruff P., Mathis C.A., Klunk W.E., Masters C.L., Rowe C.C. β-Amyloid imaging and memory in nondemented individuals: Evidence for preclinical Alzheimer's disease. Brain 2007, (in press).
205. Price D.L., Sisodia S.S. Mutant genes in familial Alzheimer's disease and transgenic models. Annual Review of Neuroscience 1998, 21:479-505.
206. Price J.C., Klunk W.E., Lopresti B.J., Lu X., Hoge J.A., Ziolko S.K., Holt D.P., Meltzer C.C., Dekosky S.T., Mathis C.A. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. Journal of Cerebral Blood Flow and Metabolism 2005, 25:1528-1547.
207. Price J.L., Morris J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Annals of Neurology 1999, 45:358-368.
208. Rabinovici G.D., Miller B.L. Frontotemporal lobar degeneration: Epidemiology, pathophysiology, diagnosis and management. CNS Drugs 2010, 24:375-398.
209. Rabinovici G.D., Rosen H.J., Alkalay A., Kornak J., Furst A.J., Agarwal N., et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011, 77:2034-2042.
210. Rabinovici G.D., Furst A.J., Alkalay A., Racine C.A., O'Neil J.P., Janabi M., et al. Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain 2010, 133:512-528.
211. Rabinovici G.D., Jagust W.J., Furst A.J., Ogar J.M., Racine C.A., Mormino E.C., et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Annals of Neurology 2008, 64:388-401.
212. Rabinovici G.D., Furst A.J., O'Neil J.P., Racine C.A., Mormino E.C., Baker S.L., Chetty S., Patel P., Pagliaro T.A., Klunk W.E., Mathis C.A., Rosen H.J., Miller B.L., Jagust W.J. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007, 68:1205-1212.
213. Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011, 134:2456-2477.
214. Ratnavalli E., Brayne C., Dawson K., Hodges J.R. The prevalence of frontotemporal dementia. Neurology 2002, 58:1615-1621.
215. Reiman E.M., Langbaum J.B., Fleisher A.S., Caselli R.J., Chen K., Ayutyanont N., et al. Alzheimer's prevention initiative: A plan to accelerate the evaluation of presymptomatic treatments. Journal of Alzheimer's Disease 2011, 3(Suppl. 26):321-329.
216. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B.S., Alexander G.E., Klunk W.E., Mathis C.A., Price J.C., Aizenstein H.J., DeKosky S.T., Caselli R.J. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009, 106(16):6820-6825.
217. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. New England Journal of Medicine 1996, 96:752-758.
218. Remes A.M., Finnila S., Mononen H., Tuominen H., Takalo R., Herva R., Majamaa K. Hereditary dementia with intracerebral hemorrhages and cerebral amyloid angiopathy. Neurology 2004, 63:234-240.
219. 11 C-PIB-PET amyloid imaging in patients with APP locus duplication. Archives of Neurology 2007, (in press).
220. Rentz D.M., Locascio J.J., Becker J.A., Moran E.K., Eng E., Buckner R.L., Sperling R.A., Johnson K.A. Cognition, reserve, and amyloid deposition in normal aging. Annals of Neurology 2010, 67:353-364.
221. Resnick S.M., Sojkova J., Zhou Y., An Y., Ye W., Holt D.P., Dannals R.F., Mathis C.A., Klunk W.E., Ferrucci L., Kraut M.A., Wong D.F. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010, 74:807-815.
222. Rinne J.O., Brooks D.J., Rossor M.N., Fox N.C., Bullock R., Klunk W.E., et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurology 2010, 9:363-372.
223. Roe C.M., Mintun M.A., D'Angelo G., Xiong C., Grant E.A., Morris J.C. Alzheimer disease and cognitive reserve: Variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Archives of Neurology 2008, 65:1467-1471.
224. Rosand J., Muzikansky A., Kumar A., Wisco J.J., Smith E.E., Betensky R.A., Greenberg S.M. Spatial clustering of hemorrhages in probable cerebral amyloid angiopathy. Annals of Neurology 2005, 58:459-462.
225. Rosen R.F., Ciliax B.J., Wingo T.S., Gearing M., Dooyema J., Lah J.J., et al. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. Acta Neuropathologica 2010, 119:221-233.
226. Rosenbloom M.H., Alkalay A., Agarwal N., Baker S.L., O'Neil J.P., Janabi M., et al. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology 2011, 76:1789-1796.
227. Rovelet-Lecrux A., Frebourg T., Tuominen H., Majamaa K., Campion D., Remes A.M. APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. Journal of Neurology Neurosurgery and Psychiatry 2007, 78:1158-1159.
228. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging 2010, 31:1275-1283.
229. Rowe C.C., Ackerman U., Browne W., Mulligan R., Pike K.L., O'Keefe G., et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: Proof of mechanism. Lancet Neurology 2008, 7:129-135.
230. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
231. Sabbagh M.N., Fleisher A., Chen K., Rogers J., Berk C., Reiman E., Pontecorvo M., Mintun M., Skovronsky D., Jacobson S.A., Sue L.I., Liebsack C., Charney A.S., Cole L., Belden C., Beach T.G. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease. Archives of Neurology 2011, 68(11):1461-1466.
232. Scheinin N.M., Aalto S., Koikkalainen J., Lötjönen J., Karrasch M., Kemppainen N., Viitanen M., Någren K., Helin S., Scheinin M., Rinne J.O. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009, 73(15):1186-1192.
233. Shimada H., Ataka S., Tomiyama T., Takechi H., Mori H., Miki T. Clinical course of patients with familial early-onset Alzheimer's disease potentially lacking senile plaques bearing the E693Δ mutation in amyloid precursor protein. Dementia and Geriatric Cognitive Disorders 2011, 32(1):45-54.
234. Shin J., Kepe V., Barrio J.R., Small G.W. The merits of FDDNP-PET imaging in Alzheimer's disease. Journal of Alzheimer's Disease 2011, 3(Suppl. 26):135-145.
235. Shin J., Lee S.Y., Kim S.H., Kim Y.B., Cho S.J. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage 2008, 43(2):236-244.
236. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., Read S., Satyamurthy N., Petric A., Huang S.C., Barrio J.R. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. The American Journal of Geriatric Psychiatry 2002, 10:24-35.
237. Small G.W., Siddarth P., Burggren A.C., Kepe V., Ercoli L.M., Miller K.J., Lavretsky H., Thompson P.M., Cole G.M., Huang S.C., Phelps M.E., Bookheimer S.Y., Barrio J.R. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch Gen Psychiatry 2009, 66(1):81-87.
238. Small G.W., Kepe V., Ercoli L.M., Siddarth P., Bookheimer S.Y., Miller K.J., Lavretsky H., Burggren A.C., Cole G.M., Vinters H.V., Thompson P.M., Huang S.C., Satyamurthy N., Phelps M.E., Barrio J.R. PET of brain amyloid and tau in mild cognitive impairment. The New England Journal of Medicine 2006, 355:2652-2663.
239. Snider B.J., Fagan A.M., Roe C., Shah A.R., Grant E.A., Xiong C., Morris J.C., Holtzman D.M. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Archives of Neurology 2009, 66(5):638-645.
240. Snowden J.S., Stopford C.L., Julien C.L., Thompson J.C., Davidson Y., Gibbons L., et al. Cognitive phenotypes in Alzheimer's disease and genetic risk. Cortex 2007, 43:835-845.
241. Sojkova J., Driscoll I., Iacono D., Zhou Y., Codispoti K.E., Kraut M.A., Ferrucci L., Pletnikova O., Mathis C.A., Klunk W.E., O'Brien R.J., Wong D.F., Troncoso J.C., Resnick S.M. In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Archives of Neurology 2011, 68(2):232-240.
242. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia 2011, 7:280-292.
243. Sperling R.A., Laviolette P.S., O'Keefe K., O'Brien J., Rentz D.M., Pihlajamaki M., Marshall G., Hyman B.T., Selkoe D.J., Hedden T., Buckner R.L., Becker J.A., Johnson K.A. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009, 63:178-188.
244. Storandt M., Head D., Fagan A.M., Holtzman D.M., Morris J.C. Toward a multifactorial model of Alzheimer disease. Neurobiol Aging 2012, [Epub ahead of print].
245. Storandt M., Mintun M.A., Head D., Morris J.C. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: Cognitive decline associated with Abeta deposition. Archives of Neurology 2009, 66(12):1476-1481.
246. Strozyk D., Blennow K., White L.R., Launer J. CSF A beta 42 levels correlate with amyloid neuropathology in a population-based autopsy study. Neurology 2003, 60:652-656.
247. Suenaga T., Hirano A., Llena J.F., Yen S.H., Dickson D.W. Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer's disease. Acta Neuropathologica 1990, 80:280-286.
248. Suotunen T., Hirvonen J., Immonen-Raiha P., Aalto S., Lisinen I., Arponen E., Teras M., Koski K., Sulkava R., Seppanen M., Rinne J.O. Visual assessment of [(11)C]PIB PET in patients with cognitive impairment. European Journal of Nuclear Medicine and Molecular Imaging 2010, 37(6):1141-1147.
249. Tang-Wai D.F., Graff-Radford N.R., Boeve B.F., Dickson D.W., Parisi J.E., Crook R., et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004, 63:1168-1174.
250. Tanzi R.E., Kovacs D.M., Kim T.W., Moir R.D., Guenette S.Y., Wasco W. The gene defects responsible for familial Alzheimer's disease. Neurobiology of Disease 1996, 3:159-168.
251. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Annals of Neurology 1991, 30(4):572-580.
252. Thal D.R., Rub U., Orantes M., Braak H. Phases of Ab-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58:1791-1800.
253. Theuns J., Marjaux E., Vandenbulcke M., Van Laere K., Kumar-Singh S., Bormans G., Brouwers N., Van den Broeck M., Vennekens K., Corsmit E., Cruts M., De Strooper B., Van Broeckhoven C., Vandenberghe R. Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Human Mutation 2006, 27:888-896.
254. Thompson P.W., Ye L., Morgenstern J.L., Sue L., Beach T.G., Judd D.J., Shipley N.J., Libri V., Lockhart A. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. Journal of Neurochemistry 2009, 109(2):623-630.
255. Tolboom N., van der Flier W.M., Yaqub M., Boellaard R., Verwey N.A., Blankenstein M.A., Windhorst A.D., Scheltens P., Lammertsma A.A., van Berckel B.N. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. Journal of Nuclear Medicine 2009, 50(9):1464-1470.
256. Tolboom N., Yaqub M., van der Flier W.M., Boellaard R., Luurtsema G., Windhorst A.D., Barkhof F., Scheltens P., Lammertsma A.A., van Berckel B.N.M. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. Journal of Nuclear Medicine 2009, 50(2):191-197.
257. 11 C]PIB. Journal of Nuclear Medicine 2007, 48:57.
258. Tomiyama T., Nagata T., Shimada H., Teraoka R., Fukushima A., Kanemitsu H., Takuma H., Kuwano R., Imagawa M., Ataka S., Wada Y., Yoshioka E., Nishizaki T., Watanabe Y., Mori H. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Annals of Neurology 2008, 63(3):377-387.
259. van de Pol L.A., van der Flier W.M., Korf E.S., Fox N.C., Barkhof F., Scheltens P. Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology 2007, 69(15):1491-1497.
260. Vandenberghe R., Van Laere K., Ivanoiu A., Salmon E., Bastin C., Triau E., Hasselbalch S., Law I., Andersen A., Korner A., Minthon L., Garraux G., Nelissen N., Bormans G., Buckley C., Owenius R., Thurfjell L., Farrar G., Brooks D.J. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Annals of Neurology 2010, 68(3):319-329.
261. Venneti S., Lopresti B.J., Wang G., Hamilton R.L., Mathis C.A., Klunk W.E., Apte U.M., Wiley C.A. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiology of Aging 2009, 30(8):1217-1226.
262. Villemagne V.L., Okamura N., Pejoska S., Drago J., Mulligan R.S., Chetelat G., O'Keefe G.G., Jones G., Kung H.F., Pontecorvo M., Masters C.L., Skovronsky D.M., Rowe C.C. Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging. Neuro-Degenerative Diseases 2012, Jan 17. [Epub ahead of print].
263. Villemagne V.L., Ong K., Mulligan R.S., Holl G., Pejoska S., Jones G., O'Keefe G., Ackerman U., Tochon-Danguy H., Chan J.G., Reininger C.B., Fels L., Putz B., Rohde B., Masters C.L., Rowe C.C. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. Journal of Nuclear Medicine 2011, 52:1210-1217.
264. Villemagne V.L., Pike K.E., Chételat G., Ellis K.A., Mulligan R.S., Bourgeat P., Ackermann U., Jones G., Szoeke C., Salvado O., Martins R., O'Keefe G., Mathis C.A., Klunk W.E., Ames D., Masters C.L., Rowe C.C. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Annals of Neurology 2011, 69(1):181-192.
265. Villemagne V.L., McLean C.A., Reardon K., Boyd A., Lewis V., Klug G., Jones G., Baxendale D., Masters C.L., Rowe C.C., Collins S.J. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. Journal of Neurology Neurosurgery and Phychiatry 2009, 80(9):998-1001.
266. Villemagne V.L., Pike K.E., Darby D., Maruff P., Savage G., Ng S., Ackermann U., Cowie T.F., Currie J., Chan S.G., Jones G., Tochon-Danguy H., O'Keefe G., Masters C.L., Rowe C.C. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008, 46:1688-1697.
267. Vlassenko A.G., Mintun M.A., Xiong C., Sheline Y.I., Goate A.M., Benzinger T.L., Morris J.C. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Annals of Neurology 2011, 70(5):857-861.
268. Wang H., Golob E., Bert A., Nie K., Chu Y., Dick M.B., Mandelkern M., Su M.Y. Alterations in regional brain volume and individual MRI-guided perfusion in normal control, stable mild cognitive impairment, and MCI-AD converter. Journal of Geriatric Psychiatry and Neurology 2009, 22(1):35-45.
269. Whitaker C., Eckman C., Almeida C., Feinstein D., Atwood C., Eckman E., Crutcher K., Hersh L., Leissring M., LaVoie M., Ertekin-Taner N., Shapiro P., Takahashi R., Yamin R., Mansourian S., Estus S., Lesne S., Turner T., Farris W., Stroebel G. Live discussion: Amyloid-beta degradation: The forgotten half of Alzheimer's disease. 12 September 2002. Journal of Alzheimer's Disease 2003, 5:491-497.
270. Wilcox K.C., Lacor P.N., Pitt J., Klein W.L. Aβ oligomer-induced synapse degeneration in Alzheimer's disease. Cellular and Molecular Neurobiology 2011, 31(6):939-948.
271. Wolf D.S., Gearing M., Snowdon D.A., Mori H., Markesbery W.R., Mirra S.S. Progression of regional neuropathology in Alzheimer disease and normal elderly: Findings from the Nun study. Alzheimer Disease & Associated Disorders 1999, 13:226-231.
272. Wolk D.A., Grachev I.D., Buckley C., Kazi H., Grady M.S., Trojanowski J.Q., Hamilton R.H., Sherwin P., McLain R., Arnold S.E. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Archives of Neurology 2011, 68(11):1398-1403.
273. Wolk D.A., Price J.C., Saxton J.A., Snitz B.E., James J.A., Lopez O.L., Aizenstein H.J., Cohen A.D., Weissfeld L.A., Mathis C.A., Klunk W.E., De-Kosky S.T. Amyloid imaging in mild cognitive impairment subtypes. Archives of Neurology 2009, 65(5):557-568.
274. Wong D.F., Rosenberg P.B., Zhou Y., Kumar A., Raymont V., Ravert H.T., Dannals R.F., Nandi A., Brasić J.R., Ye W., Hilton J., Lyketsos C., Kung H.F., Joshi A.D., Skovronsky D.M., Pontecorvo M.J. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). Journal of Nuclear Medicine 2010, 51(6):913-920.
275. Xia W., Ostaszewski B.L., Kimberly W.T., Rahmati T., Moore C.L., Wolfe M.S., Selkoe D.J. FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: Evidence for direct involvement of PS1 in the gamma-secretase cleavage complex. Neurobiology of Disease 2000, 7:673-681.
276. Younkin S.G. The APP and PS1/2 mutations linked to early onset familial Alzheimer's disease increase the extracellular concentration and A beta 1-42(43). Rinshō Shinkeigaku = Clinical Neurology 1997, 37:1099.
277. Yuan Y., Gu Z.X., Wei W.S. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: A meta-analysis. AJNR. American Journal of Neuroradiology 2009, 30(2):404-410.
278. Ziolko S.K., Weissfeld L.A., Klunk W.E., Mathis C.A., Hoge J.A., Lopresti B.J., Dekosky S.T., Price J.C. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage 2006, 33:94-102.